NCT06813924View on ClinicalTrials.gov

A Research Study of the Effect of Etavopivat on Other Drugs in Healthy Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

37

Participants

Timeline

Start Date

February 6, 2025

Primary Completion Date

May 27, 2025

Study Completion Date

May 27, 2025

Conditions
Healthy Volunteers Sickle Cell Disease, Thalassemia
Interventions
DRUG

Etavopivat

Participants will receive a daily dose of etavopivat orally.

DRUG

Digoxin

Participants will receive a single dose of digoxin orally.

DRUG

Pitavastatin

Participants will receive a single dose of pitavastatin orally.

DRUG

Metformin

Participants will receive a single dose of metformin orally.

DRUG

Midazolam

Participants will receive a single dose of midazolam orally.

DRUG

Rosuvastatin

Participants will receive a single dose of rosuvastatin orally.

Trial Locations (1)

84124

ICON-Salt Lake City, Salt Lake City

Sponsors

Lead Sponsor

Novo Nordisk A/S
All Listed Sponsors
lead

Novo Nordisk A/S

INDUSTRY